Clinical Trial Update: Autologous Bone Marrow-derived Mononuclear Cells for Acute Spinal Cord Injury [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating autologous bone marrow-derived mononuclear cells for acute spinal cord injury.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury

Drugs mentioned

• Autologous bone marrow-derived mononuclear cells (bone marrow-derived mononuclear cells)

Snippet

Sponsor: Shanghai Changzheng Hospital | Conditions: Spinal Cord Injury | Phase 2 | Status: UNKNOWN